Topics

Akcea and Pfizer Announce Licensing Agreement for Antisense Therapy being Investigated for Cardiovascular and Metabolic Diseases

09:24 EDT 8 Oct 2019 | Speciality Pharma Journal

BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular …

Original Article: Akcea and Pfizer Announce Licensing Agreement for Antisense Therapy being Investigated for Cardiovascular and Metabolic Diseases

NEXT ARTICLE

More From BioPortfolio on "Akcea and Pfizer Announce Licensing Agreement for Antisense Therapy being Investigated for Cardiovascular and Metabolic Diseases"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...